Thermo Fisher Scientific Q4 2025 Earnings Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5d ago
0mins
Should l Buy TMO?
Source: seekingalpha
- Strong Financial Performance: Thermo Fisher reported Q4 2025 revenue of $12.21 billion, a 7% year-over-year increase, with adjusted EPS at $6.57, reflecting excellent execution and operational performance throughout the year.
- Innovative Product Launches: The company introduced several new products, including the Thermo Scientific Orbitrap Astral Zoom, receiving extremely positive customer feedback, which is expected to accelerate research and enhance scientific breakthroughs, thereby solidifying its market position.
- Strategic Acquisition Plans: Thermo Fisher announced the acquisition of Clario for approximately $9 billion, expected to close by mid-2026, which is projected to add $0.45 to adjusted EPS, demonstrating the company's proactive approach to expanding its business and enhancing profitability.
- 2026 Financial Guidance: The company initiated revenue guidance for 2026 between $46.3 billion and $47.2 billion, with adjusted EPS projected at $24.22 to $24.80, reflecting confidence in future growth while remaining mindful of macroeconomic uncertainties.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMO
Wall Street analysts forecast TMO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMO is 658.89 USD with a low forecast of 580.00 USD and a high forecast of 750.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 581.770
Low
580.00
Averages
658.89
High
750.00
Current: 581.770
Low
580.00
Averages
658.89
High
750.00
About TMO
Thermo Fisher Scientific Inc. is engaged in accelerating life sciences research, solving complex analytical challenges, increasing laboratory productivity, and improving patient health through diagnostics and the development and manufacture of life-changing therapies. Through its Life Sciences Solutions segment, it provides a portfolio of reagents, instruments and consumables used in biological and medical research, the discovery and production of new drugs and vaccines as well as diagnosis of infection and disease. Through its Analytical Instruments segment, it provides instruments and the supporting consumables, software and services that are used for a range of applications. Its Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. It also provides purification and filtration technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Revvity Reports Strong Q4 2025 Earnings, Exceeds Expectations
- Earnings Growth: Revvity reported adjusted earnings of $1.70 per share for Q4 2025, a 19.7% year-over-year increase that surpassed the consensus estimate of $1.55, indicating robust profitability and competitive strength.
- Sales Increase: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting sustained demand for its products in the market.
- Life Sciences Segment Performance: The Life Sciences segment generated $382 million in revenue, a 2% increase, although academic and government demand declined, the growth from pharma and biotech partially offset this, showcasing the segment's resilience.
- Future Guidance: Revvity forecasts adjusted earnings for fiscal 2026 to be between $5.35 and $5.45 per share, with sales projected at $2.96 billion to $2.99 billion, reflecting a year-over-year growth of 4%-5%, indicating the company's confidence and strategic planning for future market conditions.
See More
Thermo Fisher Scientific Q4 2025 Earnings Highlights
- Strong Financial Performance: Thermo Fisher reported Q4 2025 revenue of $12.21 billion, a 7% year-over-year increase, with adjusted EPS at $6.57, reflecting excellent execution and operational performance throughout the year.
- Innovative Product Launches: The company introduced several new products, including the Thermo Scientific Orbitrap Astral Zoom, receiving extremely positive customer feedback, which is expected to accelerate research and enhance scientific breakthroughs, thereby solidifying its market position.
- Strategic Acquisition Plans: Thermo Fisher announced the acquisition of Clario for approximately $9 billion, expected to close by mid-2026, which is projected to add $0.45 to adjusted EPS, demonstrating the company's proactive approach to expanding its business and enhancing profitability.
- 2026 Financial Guidance: The company initiated revenue guidance for 2026 between $46.3 billion and $47.2 billion, with adjusted EPS projected at $24.22 to $24.80, reflecting confidence in future growth while remaining mindful of macroeconomic uncertainties.
See More
Thermo Fisher Reports Strong Q4 2025 Earnings Beat
- Earnings Beat: Thermo Fisher reported adjusted Q4 2025 earnings of $6.57 per share, surpassing the expected $6.45, demonstrating robust performance amid a challenging external environment.
- Significant Sales Growth: Quarterly sales reached $12.22 billion, a 7% year-over-year increase, exceeding analyst consensus of $11.95 billion, indicating sustained competitive strength in the market.
- Strong Segment Performance: Life Sciences Solutions sales rose 13.1% to $2.95 billion, while Laboratory Products and Biopharma Services sales increased 7.5% to $6.38 billion, reflecting the effectiveness of strategic investments in key areas.
- Optimistic 2026 Outlook: The company projects 2026 revenue growth of 4%-6%, targeting $46.3-$47.2 billion, with adjusted earnings expected between $24.22 and $24.80 per share, showcasing strong growth potential and market confidence.
See More
This Successful Fund Manager Favors J&J, Lowe’s, and Utility Stocks
- Active Equity Managers: Few active equity managers consistently outperform the S&P 500 index.
- Long-Term Consistency: It is even rarer for these managers to achieve consistent success over many years.
See More
Thermo Fisher's Stock Drops 3.5% Following Lower-Than-Expected 2026 Profit Forecast
- Stock Performance: Thermo Fisher's shares have decreased by 3.5% following recent forecasts.
- Profit Projections: The company's profit for 2026 is now expected to fall below previous estimates.
See More
THERMO FISHER SCIENTIFIC EXECUTIVE STATES FORECAST RELIES ON CURRENT TARIFFS
Forecasting Methodology: The article discusses the scientific methods used by thermofisher scientists to create accurate forecasts based on current tariffs.
Impact of Tariffs: It highlights how existing tariffs influence the forecasting process and the implications for various stakeholders.
See More
Revvity Reports Strong Q4 2025 Earnings, Exceeds Expectations
- Earnings Growth: Revvity reported adjusted earnings of $1.70 per share for Q4 2025, a 19.7% year-over-year increase that surpassed the consensus estimate of $1.55, indicating robust profitability and competitive strength.
- Sales Increase: The company achieved sales of $772.06 million, up 6% year-over-year with 4% organic growth, exceeding the market expectation of $761.29 million, reflecting sustained demand for its products in the market.
- Life Sciences Segment Performance: The Life Sciences segment generated $382 million in revenue, a 2% increase, although academic and government demand declined, the growth from pharma and biotech partially offset this, showcasing the segment's resilience.
- Future Guidance: Revvity forecasts adjusted earnings for fiscal 2026 to be between $5.35 and $5.45 per share, with sales projected at $2.96 billion to $2.99 billion, reflecting a year-over-year growth of 4%-5%, indicating the company's confidence and strategic planning for future market conditions.
See More
Thermo Fisher Scientific Q4 2025 Earnings Highlights
- Strong Financial Performance: Thermo Fisher reported Q4 2025 revenue of $12.21 billion, a 7% year-over-year increase, with adjusted EPS at $6.57, reflecting excellent execution and operational performance throughout the year.
- Innovative Product Launches: The company introduced several new products, including the Thermo Scientific Orbitrap Astral Zoom, receiving extremely positive customer feedback, which is expected to accelerate research and enhance scientific breakthroughs, thereby solidifying its market position.
- Strategic Acquisition Plans: Thermo Fisher announced the acquisition of Clario for approximately $9 billion, expected to close by mid-2026, which is projected to add $0.45 to adjusted EPS, demonstrating the company's proactive approach to expanding its business and enhancing profitability.
- 2026 Financial Guidance: The company initiated revenue guidance for 2026 between $46.3 billion and $47.2 billion, with adjusted EPS projected at $24.22 to $24.80, reflecting confidence in future growth while remaining mindful of macroeconomic uncertainties.
See More
Thermo Fisher Reports Strong Q4 2025 Earnings Beat
- Earnings Beat: Thermo Fisher reported adjusted Q4 2025 earnings of $6.57 per share, surpassing the expected $6.45, demonstrating robust performance amid a challenging external environment.
- Significant Sales Growth: Quarterly sales reached $12.22 billion, a 7% year-over-year increase, exceeding analyst consensus of $11.95 billion, indicating sustained competitive strength in the market.
- Strong Segment Performance: Life Sciences Solutions sales rose 13.1% to $2.95 billion, while Laboratory Products and Biopharma Services sales increased 7.5% to $6.38 billion, reflecting the effectiveness of strategic investments in key areas.
- Optimistic 2026 Outlook: The company projects 2026 revenue growth of 4%-6%, targeting $46.3-$47.2 billion, with adjusted earnings expected between $24.22 and $24.80 per share, showcasing strong growth potential and market confidence.
See More
This Successful Fund Manager Favors J&J, Lowe’s, and Utility Stocks
- Active Equity Managers: Few active equity managers consistently outperform the S&P 500 index.
- Long-Term Consistency: It is even rarer for these managers to achieve consistent success over many years.
See More
Thermo Fisher's Stock Drops 3.5% Following Lower-Than-Expected 2026 Profit Forecast
- Stock Performance: Thermo Fisher's shares have decreased by 3.5% following recent forecasts.
- Profit Projections: The company's profit for 2026 is now expected to fall below previous estimates.
See More
THERMO FISHER SCIENTIFIC EXECUTIVE STATES FORECAST RELIES ON CURRENT TARIFFS
Forecasting Methodology: The article discusses the scientific methods used by thermofisher scientists to create accurate forecasts based on current tariffs.
Impact of Tariffs: It highlights how existing tariffs influence the forecasting process and the implications for various stakeholders.
See More
